Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials

To our knowledge, this is the largest analysis of HER2 status in patients with untreated mCRC enrolled in RCT. Waiting for targeted approaches, HER2-pos and mut do not predict benefit from bev/anti-EGFRs and should be regarded as negative prognostic factors in pMMR/MSS <i>RAS/BRAF</i> wild-type mCRC.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-09-04
DOI
https://doi.org/10.1200/jco-25-01003
Citations
10
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
10.45
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials

Junpei Soeda, Marco Maria Germani, Clara Ugolini, Arndt Stahler et al.
10 citations
Journal of Clinical Oncology
Colorectal Cancer Treatments and Studies
10.45
article

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials

Junpei Soeda, Marco Maria Germani, Clara Ugolini, Arndt Stahler, Kohei Shitara, Yoshiaki Nakamura, Francesca Battaglin, Lisa Salvatore, Francesca Bergamo, Tadayoshi Hashimoto, Alan P. Venook, Heinz‐Josef Lenz, Sara Lonardi, Dominik Paul Modest, Takayuki Yoshino, Eiji Oki, Beatrice Borelli, Kei Muro, Filippo Pietrantonio, Carlotta Antoniotti, Simone Oldani, Chiara Cremolini
article en
10 citations

Abstract

To our knowledge, this is the largest analysis of HER2 status in patients with untreated mCRC enrolled in RCT. Waiting for targeted approaches, HER2-pos and mut do not predict benefit from bev/anti-EGFRs and should be regarded as negative prognostic factors in pMMR/MSS <i>RAS/BRAF</i> wild-type mCRC.

Journal of Clinical OncologyVol. 43(29)
Università Cattolica del Sacro Cuore (IT), University of Pisa (IT), Kyushu University (JP), Agostino Gemelli University Polyclinic (IT), Istituto Oncologico Veneto (IT), USC Norris Comprehensive Cancer Center (US), Aichi Cancer Center (JP), National Cancer Center Hospital East (JP), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Azienda Ospedaliera Universitaria Pisana (IT), UCSF Helen Diller Family Comprehensive Cancer Center (US), Takeda (Japan) (JP), Charité - Universitätsmedizin Berlin (DE)
Openalex Percentile: Top 1%
Colorectal Cancer Treatments and Studies
10.45
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.